[go: up one dir, main page]

WO2012030309A3 - Formulation d'un inhibiteur des canaux calciques - Google Patents

Formulation d'un inhibiteur des canaux calciques Download PDF

Info

Publication number
WO2012030309A3
WO2012030309A3 PCT/TR2011/000199 TR2011000199W WO2012030309A3 WO 2012030309 A3 WO2012030309 A3 WO 2012030309A3 TR 2011000199 W TR2011000199 W TR 2011000199W WO 2012030309 A3 WO2012030309 A3 WO 2012030309A3
Authority
WO
WIPO (PCT)
Prior art keywords
tiotropium
calcium channel
channel blocker
formulation
copd
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/TR2011/000199
Other languages
English (en)
Other versions
WO2012030309A2 (fr
Inventor
Mahmut Bilgic
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to EP11767092.7A priority Critical patent/EP2611447A2/fr
Publication of WO2012030309A2 publication Critical patent/WO2012030309A2/fr
Publication of WO2012030309A3 publication Critical patent/WO2012030309A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne une formulation de poudre sèche, comprenant au moins un inhibiteur des canaux calciques et le tiotropium, qui a été développée pour être utilisée dans le traitement des maladies des voies respiratoires tel que l'asthme et la BPCO.
PCT/TR2011/000199 2010-09-01 2011-08-24 Formulation d'un inhibiteur des canaux calciques Ceased WO2012030309A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP11767092.7A EP2611447A2 (fr) 2010-09-01 2011-08-24 Formulation comprenant le tiotropium et un inhibiteur des canaux calciques

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR2010/07251A TR201007251A2 (tr) 2010-09-01 2010-09-01 Kalsiyum kanal blokörü formülasyonu.
TR2010/07251 2010-09-01

Publications (2)

Publication Number Publication Date
WO2012030309A2 WO2012030309A2 (fr) 2012-03-08
WO2012030309A3 true WO2012030309A3 (fr) 2012-08-09

Family

ID=44764205

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2011/000199 Ceased WO2012030309A2 (fr) 2010-09-01 2011-08-24 Formulation d'un inhibiteur des canaux calciques

Country Status (3)

Country Link
EP (1) EP2611447A2 (fr)
TR (1) TR201007251A2 (fr)
WO (1) WO2012030309A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011041595A1 (fr) * 2009-09-30 2011-04-07 Microdose Therapeutx, Inc. Procédés et compositions pour le traitement du phénomène de raynaud
JP6092015B2 (ja) * 2013-06-19 2017-03-08 日本碍子株式会社 単結晶体の製造方法

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR890004691B1 (ko) * 1985-07-02 1989-11-25 키 파마슈티칼스, 인코포레이티드 만성 폐색성 폐질환의 치료용 및 조성물
US20020106332A1 (en) * 2000-10-12 2002-08-08 Michael Walz Process for preparing powder formulations
US20020110529A1 (en) * 2000-10-12 2002-08-15 Karoline Bechtold-Peters Inhalable powder containing tiotropium
US20030018019A1 (en) * 2001-06-23 2003-01-23 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions based on anticholinergics, corticosteroids and betamimetics
WO2003088944A1 (fr) * 2002-04-13 2003-10-30 Glaxo Group Limited Composition de poudre seche a inhaler
WO2008152398A2 (fr) * 2007-06-14 2008-12-18 Cipla Limited Formulations pour inhalation
US20090088408A1 (en) * 2001-06-23 2009-04-02 Meade Christopher J M Pharmaceutical compositions on anticholinergics, corticosteroids and betamimetics

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003535096A (ja) 2000-05-30 2003-11-25 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド ジヒドロピリジンソフトドラッグならびに関連する組成物及び方法

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR890004691B1 (ko) * 1985-07-02 1989-11-25 키 파마슈티칼스, 인코포레이티드 만성 폐색성 폐질환의 치료용 및 조성물
US20020106332A1 (en) * 2000-10-12 2002-08-08 Michael Walz Process for preparing powder formulations
US20020110529A1 (en) * 2000-10-12 2002-08-15 Karoline Bechtold-Peters Inhalable powder containing tiotropium
US20030018019A1 (en) * 2001-06-23 2003-01-23 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions based on anticholinergics, corticosteroids and betamimetics
US20090088408A1 (en) * 2001-06-23 2009-04-02 Meade Christopher J M Pharmaceutical compositions on anticholinergics, corticosteroids and betamimetics
WO2003088944A1 (fr) * 2002-04-13 2003-10-30 Glaxo Group Limited Composition de poudre seche a inhaler
WO2008152398A2 (fr) * 2007-06-14 2008-12-18 Cipla Limited Formulations pour inhalation

Also Published As

Publication number Publication date
WO2012030309A2 (fr) 2012-03-08
TR201007251A2 (tr) 2012-03-21
EP2611447A2 (fr) 2013-07-10

Similar Documents

Publication Publication Date Title
WO2011131943A3 (fr) Compositions pharmaceutiques
IL221133A (en) Process, tube and device for preparation of wound healing preparation
WO2011152804A3 (fr) Procédé pour formulations pulvérulentes sèches
ZA201503554B (en) Compositions for balancing gut microbiota and the preparation and the uses thereof
ZA201209475B (en) Compositions comprising a near terminal-branched compound and methods of making the same
IL222268A (en) Preserved pyrollo-pyridines, containing pharmaceutical preparations, combined preparations containing them and their use in the preparation of medicines
IL226448A (en) A m72 antigen-containing immunosuppressant drug and its uses for drug preparation
WO2012110770A3 (fr) Composition pharmaceutique
WO2012016889A3 (fr) Formulation de poudre sèche comprenant un inhibiteur de phosphodiestérase
EP3013348A4 (fr) Composition médicamenteuse constituée d'un extrait d'amarante à teneur enrichie en nitrate et son procédé de préparation
WO2010094731A3 (fr) Composition pharmaceutique a inhaler
WO2011141685A3 (fr) Compositions nasales a visee systemique a base de cocoyl proline ou d'au moins un de ses constituants
IL222723A0 (en) Respiratory syncytial virus antigenic compositions and methods
EP2370068A4 (fr) Procédés et compositions pour la délivrance de médicaments aux poumons
ZA201500208B (en) Dry powder for inhalation formulation comprising salmeterol xinafoate, fluticasone propionate and tiotropium bromide, and method for preparing same
SG10201502583VA (en) Immunogenic proteins and compositions for the treatment and prevention of streptococcus agalactiae
EP2560626A4 (fr) Compositions pour émulsions à effet anésthésique local, procédés de fabrication et procédés d'utilisation
EP2995614B8 (fr) Processus catalysés par des métaux de transition pour la préparation de composés de n-allyle et leur utilisation
IL213737A0 (en) Dry powder pharmaceutical compositions for inhalation and uses thereof
EP2542059A4 (fr) Compositions comportant de l'acide myristique et leurs utilisations
IL226174A0 (en) Impulse preparations and methods for their preparation
WO2012030309A3 (fr) Formulation d'un inhibiteur des canaux calciques
WO2012030308A3 (fr) Formulation comprenant la cellobiose
EP2866792A4 (fr) Formulations de microparticules pour la délivrance au système respiratoire inférieur et central et procédés de fabrication
IL217137A0 (en) Medicinal and herbal composition and uses thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11767092

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2011767092

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE